| 0.556 -0.054 (-8.85%) | 03-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.73 |
1-year : | 0.81 |
| Resists | First : | 0.62 |
Second : | 0.69 |
| Pivot price | 0.6 |
|||
| Supports | First : | 0.51 |
Second : | 0.42 |
| MAs | MA(5) : | 0.6 |
MA(20) : | 0.6 |
| MA(100) : | 0.73 |
MA(250) : | 0.95 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.9 |
D(3) : | 50.1 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 2.92 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BRNS ] has closed below the lower bollinger band by 0.2%. Bollinger Bands are 22% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.64 | 0.64 - 0.65 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.52 - 0.53 | 0.53 - 0.54 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Sun, 22 Mar 2026
If You Invested $1,000 in Barinthus Biotherapeutics plc (BRNS) - Stock Titan
Wed, 18 Mar 2026
Barinthus Biotherapeutics plc - Depositary Receipt (BRNS) price target increased by 10.00% to 5.61 - MSN
Wed, 18 Mar 2026
Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings Summary - TradingView
Mon, 16 Mar 2026
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Finviz
Sat, 14 Mar 2026
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Fri, 13 Mar 2026
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 40.9 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -62.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|